Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. by Hejna, M. et al.
British Joumal ofCancer(1998) 78(6), 760-764
© 1998 Cancer Research Campaign
Reinduction therapy with the same cytostatic regimen
in patients with advanced colorectal cancer
M Hejna1, GV Kornek1, M Raderer1, D Depisch2, T Brodowicz1, WCC Fiebiger1 and W Scheithauer1
'Department of Internal Medicine I, Division of Oncology, University Medical School, Wahringer Gurtel 18-20, A-1090 Vienna; 2Department of Surgery,
Wr. Neustadt General Hospital, Corvinusring 3-5, A-2700 Wr.Neustadt Austria
Summary The aim of the study was to investigate the therapeutic value of reinduction therapy with the same cytostatic treatment that had
been used for induction treatment in patients with metastatic colorectal cancer. A total of 71 patients, all of whom had responded or achieved
stable disease lasting >12 weeks after six monthly courses of first-line treatment with 5-fluorouracil + racemic leucovorin (5-FU/LV; n = 35) or
5-FU plus the I-isomer of LV (LLV; n = 34) were entered in this study. At the time of relapse, the same treatment was used for initial therapy:
racemic LV or LLV was administered at 100 mg m-2 day-' by i.v. bolus injection, immediately followed by 5-FU 400 mg m-2 day-1 given as a
2-h infusion. Chemotherapeutic drugs were given on 5 consecutive days at 4-week intervals x 6 or until there was evidence of tumour
progression. Among 49 evaluable patients, reinduction therapy that was initiated after a median treatment-free interval of 5.4 months (range
3-14.5) resulted in nine partial response (PR) (18%) and 26 stable disease (SD) (53%), yielding an overall tumour control rate of 69% (95%
confidence interval, 54.6-81.7%). The median time to treatment failure from reinduction was 6.4 months, and the median survival duration
from reinduction was 8.9 months (20.1 months as judged from the beginning of induction therapy). The toxicity associated with retreatment
was generally mild to moderate; compared with initial treatment, there was no significant difference in terms of the overall rate (P = 0.33) or
severity (P = 0.19) of adverse reactions. Our data suggest that in patients with advanced colorectal cancer an interrupted treatment strategy,
i.e. retreatment with the same regimen in case of relapse .3 months after discontinuation of 6 months of successful treatment with 5-FU/LV
or 5-FU/LLV is an acceptable therapeutic concept.
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Advanced colorectal cancer remains a therapeutic challenge to
clinicians involved in the management of this common malignant
disease, which continues to be the second leading cause of cancer
death in the Western world (Chu et al, 1994). Despite intensive
efforts to improve the poor prognosis of patients with advanced
colorectal cancer, therapeutic progress has been hampered by its
apparent chemotherapeutic refractoriness. Although randomized
trials have established with reasonable certainty that
fluorouracil/leucovorin-based chemotherapy results in substantive
therapeutic gain compared with best supportive care (The Nordic
Gastrointestinal Tumour Adjuvant Therapy Group, 1992;
Scheithauer et al, 1993) or treatment with 5-FU alone (Poon et al,
1989; Advanced Colorectal Cancer Meta-Analysis Project, 1992),
there is considerable room for further improvement in terms ofthe
response rates and tolerance of treatment. Until now, it has not
been possible to define the optimal regimen ofbiochemical modu-
lation of fluoropyrimidines (Doroshow, 1996), and there is also
sparse information in terms ofthe optimal duration oftreatment in
the palliative setting. In the majority of clinical trials for the treat-
ment of advanced colorectal cancer, in fact, cyclic chemotherapy
has been used, in which 5-FU and leucovorin (or other biochem-
ical modulators/cytotoxic drugs) are administered until disease
progression, death or intolerable side-effects occur. Based on the
rationale of exposing the tumour to a maximum amount of the
Received 5August 1997
Revised 6 March 1998
Accepted 17March 1998
Correspondence to: M Hejna
cytotoxic drug while it is still chemoresponsive, continuous treat-
ment might nevertheless have certain disadvantages compared
with an interrupted treatment strategy, i.e. interruption of therapy
in patients with stable disease or objective response and reinstitu-
tion ofthe same regimen upon evidence of second progression.
A treatment-free interval might prevent or at least slow down
the development ofdrug resistance, which seems desirable in view
of the continuing need for better salvage treatment. (Available
second-line treatment options, such as irinotecan and various 5-FU
continuous infusion schedules ± oxaliplatin (Schmoll, 1996) can
still be offered at the time of reinduction failure.) A reduction in
the time on treatment is also likely to reduce the cumulative risk
for adverse toxic effects and thus contribute to improving the
individuals' quality oflife. Finally, the reduced costs for cytotoxic
drugs, for concomitant medications and hospital visits are also
potential advantages of such an interrupted treatment strategy,
which is currently recommended only in cancers potentially
curable with chemotherapy (Fisher et al, 1979; Ihde et al, 1993)
The aim of the present investigation was to evaluate the
principal therapeutic efficacy of reinduction therapy in 5-
FU/leucovorin-responsive patients with advanced colorectal
cancer experiencing progression after a treatment-free interval.
Specifically, we intended to determine the response rate and toler-
ance ofretreatment with an identical regimen to that used for first-
line therapy.
PATIENTS AND METHODS
This study is a prospective evaluation including all patients from
two treatment centres who had achieved complete response (CR),
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partial response (PR) or stable disease (SD) after 6 months offirst-
line chemotherapy with 5-fluorouracil plus racemic leucovorin
(LV) or 5-FU plus the 1-isomer of leucovorin (LLV) in a random-
ized phase III study that has been reported previously (Scheithauer
et al, 1997). As defined in the original study protocol, patients
eligible for reinduction had to have histologically confirmed
metastatic or recurrent colorectal cancer, bidimensionally measur-
able and progressive disease, a World Health Organization (WHO)
performance status score of 0 to 3, an adequate bone marrow
reserve (leucocyte count > 3500 tl ', platelet count > 100 000
gl-1) and adequate renal (serum creatinine concentration < 132
ltmol) and hepatic functions (serum bilirubin level < 34 gmol 1-'
and serum transaminase level <100 IU 1-').
Patients who progressed during or relapsed within 3 months
after completing induction therapy were not to be included in this
study, and were treated at the investigators' discretion. All other
patients were to receive the same treatment as given for induction
at the time of relapse (defined as progression of measurable
tumour of at least 25% in size or the appearance of new metas-
tases). Chemotherapy with 5-FU and LV or LLV was given intra-
venously (i.v.), as previously described. Racemic LV
(Calciumfolinat, Ebewe Arzneimittel, Unterach, Austria) or LLV
(L-Leukovorin, Lederle-Cyanamid, Vienna, Austria) was adminis-
tered at 100mg m-2 day-' by i.v. bolus injection, immediately
followed by 5-FU 400 mg m-2 day-' given as a 2-h infusion.
Chemotherapeutic drugs were given on 5 consecutive days at 4-
week intervals, again for a total of six courses or until there was
evidence of tumour progression. In patients who had experienced
WHO grade 3 or 4 toxicity during first-line treatment, the 5-FU
starting dosage was reduced by 20%. Dose modifications of rein-
duction were the same as for induction; similarly, treatments were
to be delayed weekly ifpatients had not recovered from toxicity.
Before initiating reinduction therapy, all patients were assessed
by physical examination, routine haematology and biochemistry
analyses, chest radiograph and computerized tomographic scan of
the abdomen and pelvis. Complete blood counts were repeated
weekly during chemotherapy; all other adverse reactions were
recorded and graded for severity before the next treatment cycle.
Measurable disease was reassessed every 8 weeks according to
WHO standard criteria (WHO, 1979). Objective responses on
induction/reinduction therapy had to be confirmed in one subse-
quent examination after a 4-week interval, and were reviewed by
an independent panel of oncologists and radiologists. Time to
treatment failure (defined as the time from start of reinduction
therapy to progression or relapse) and survival were calculated
using the Kaplan-Meier method (Kaplan and Meier, 1958).
RESULTS
Between June 1992 and May 1995, a total of 112 patients had been
accrued for first-line chemotherapy with 5-FU/LV or 5-FU/LLV at
the Vienna University Medical School and the General Hospital of
Wr. Neustadt, Austria. Ofthese, 71 (35 in the 5-FU/LV arm and 36
in the 5-FU/LLV arm) had responded or achieved SD after six
courses, and were thus potentially eligible to be entered on this
protocol. Only 49 were analysed, however, as 22 patients were
considered ineligible for the reinduction part of the study for the
following reasons. Seven patients had progression of disease
during or within 3 months after discontinuation of induction
therapy, and three patients had not shown objective disease
progression when reinduction therapy was started. Five patients
Table 1 Patient characteristics
Number of patients
Entered
Evaluable
Sex
Male
Female
Age (years)
Median
Range
Performance status
WHO 0-1
WHO 2-3
Location of primary tumour
Colon
Rectum
Histological grading
Gl
G2
G3
Location of metastases
Liver
Lung
Abdominopelvic mass
Lymph nodes ± bone
Number of metastatic sites
Single
Multiple
Prior first-line chemotherapy
5-Fluorouracil + racemic leucovorin
5-Fluorouracil + I-leucovorin
71
49
28
21
65.5
37-75
27
22
29
20
6
38
5
34
14
24
5
28
21
23
26
did not meet other eligibility criteria at the start of reinduction
because of poor performance status (n = 2) or hepatic dysfunction
(n = 3), four patients refused, two had developed other systemic
disease before reinduction and one patient was excluded because
ofsimultaneous radiation ofmeasurable disease at the start ofrein-
duction. Among the 49 evaluable patients, the median time to
progression from the date at which first-line chemotherapy was
initiated to the start ofreinduction therapy was 12.5 months (range
9-35); this interval included a median treatment-free interval of
5.4 months (range 3-14.5). Patient characteristics at the time
reinduction therapy was initiated are shown in Table 1. The
predominant sites of metastases were liver in 34, lung in 14,
abdominopelvic mass in 24 and soft-tissue and/or bone in five
patients. A total of 172 treatment cycles were administered for
reinduction (median 4; range 1-6).
Anti-tumour activity
Nine patients had a PR after reinduction with a median duration of
5.3 months (range 3-1 1), yielding an overall response rate of 18%
(95% confidence interval, 8.8-32%). Twenty-five patients (51%)
had SD for a median duration of 6.3 months (range 3-10), and 15
patients (31%) had PD. As shown in Table 2, in the five patients
achieving CR after first-line chemotherapy, reinduction treatment
resulted in two PR, two SD and 1 PD respectively. Among the 20
patients exhibiting partial response after induction therapy, six
experienced another PR, 11 SD and three patients were rated
progressive. Twenty-four patients with SD after induction therapy
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Table 2 Response by prior treatment response
Responseto No. of PR NC PD
first-line treatment patients No. (%) 95% Cl No. (%) 95% Cl No. (%) 95% Cl
Complete response (CR) 5 2 (40) 5-85 2 (40) 5-85 1 (20) 1-72
Partial response (PR) 20 6 (30) 12-54 11(55) 32-77 3 (15) 3-38
Stable disease (SD) 24 1 (4) 1-21 12 (50) 29-71 11(46) 26-67
Total 49 9(18)9-32 25(51) 36-66 15 (31) 18-45
Table 3 Toxicity during induction and reinduction therapy (n = 49)
Induction therapy: WHO grade Reinduction therapy: WHO grade
Toxicity I II III IV II III IV
Leukopenia 10 6 2 11 9 2
Granulocytopenia 6 7 2 1 9 9 3
Thrombocytopenia 2 1 4 1
Anaemia 11 1 12 6 1
Infection 3 2 2 3
Nausea/emesis 7 6 2 6 8 1
Stomatitis 5 4 3 7 7 1
Diarrhoea 6 5 4 1 8 7 3
Alopecia 7 1 6 1
Conjunctivitis 3 1 3 2
Dermatitis 2 2 3 1
displayed 1 PR, 12 SD and 11 PD after reinduction. The median
time to second treatment failure (indicated by progression of
disease or by death from any cause) was 6.4 months (range 2-19).
Survival
The median overall survival duration from the start of palliative
first-line chemotherapy was 20.1 months (range 6-43+), and 8.9
months (range 2-26+) as judged from the beginning of reinduc-
tion. At the time ofthis report 11 patients are alive, all with PD.
Toxicity
Table 3 shows a comparative analysis of the worst ever toxicity
patterns noted in the 49 patients evaluable for induction and
reinduction therapy. Toxicity data are not reported separately for
patients treated with 5-FU/LV or 5-FU/LLV, as [apart from only a
minor difference in haematotoxicity (Scheithauer et al, 1997)] all
patients had received an identical drug regimen during the induc-
tion and reintroduction phase ofthe study. Overall, 32 (65%) ofthe
patients receiving first-line chemotherapy reported at least one
adverse reaction, and nine (18%) had at least one severe adverse
reaction. The respective values during the reinduction phase ofthe
study were 35 (71%) and 7 (14%), suggesting no difference (P =
0.33 and P = 0.19). The lack ofa difference between induction and
reinduction therapy was apparent in terms of haematological as
well as other organic side-effects. The median nadir granulocyte
counts were 3550,l-' (range 50-11 970) and 3290 tl-l (range 660-
18 800), and the median nadir platelet counts were 203 000 1l-1
(range 62 000-657 000) and 178 000 1-' (range 69 000-556 000)
in the induction and reinduction phase respectively. The most
commonly encountered non-haematological side-effects included
nausea/vomiting in 31%, diarrhoea in 33% and mucositis 24%
during first-line therapy, compared with 31%, 37%, and 31% in
patients receiving the same treatment regimen for reinduction. No
treatment-related deaths were observed.
When comparing toxicity patterns, it must be emphasized that
all 49 patients commenced first-line treatment at full dosage,
compared with only 40 patients (82%) treated during the reinduc-
tion phase. This difference is due to the fact that in the nine
patients who had experienced grade 3 or 4 toxicity during first-line
therapy, the 5-FU starting dose was reduced by 20% according to
the study protocol.
DISCUSSION
Years ago it was still a controversial issue whether patients with
advanced colorectal cancer should be treated by palliative
chemotherapy at all because of a low remission rate and only
marginal gain in survival. However, despite a low objective
response rate, about half of the patients seem to have some benefit
from fluorouracil/leucovorin-based chemotherapy in terms of
progression-free and total lifetime, as well as in quality oflife (The
Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 1992;
Scheithauer et al, 1993). It seems obvious that this improvement
should be achieved with minimal toxicity and time in the hospital,
and, in order to limit financial resources, also at minimal costs.
Although intermittent rather than 'essentially uninterrupted use of
chemotherapy until progression or death' seems more likely to
achieve this goal ofpalliative tumour therapy, the latter therapeutic
strategy is commonly used, at least in the large majority ofreported
clinical trials in solid tumours, including advanced colorectal
cancer. Although in several recently published (European) trials,
the duration of treatment has generally been limited to six
courses/months, with or without the option to continue treatment
when clinical benefit was perceived (Kohne-Womper et al, 1990,
British Journal of Cancer (1998) 78(6), 760-764 0 Cancer Research Campaign 1998Reinduction therapy in colorectal cancer 763
1992; Scheithauer et al, 1994, 1997; Stoffregen et al, 1996;
Zalcberg et al, 1996; Rougier et al, 1997), or to 4 or 12 weeks in
patients achieving CR or CR/PR/SD (Labianca et al, 1991; Jager
et al, 1996), and occasionally was to be restarted for tumour
progression (Kohne-Womper et al, 1990; Scheithauer et al, 1994;
Stoffregen et al, 1996; Jager et al, 1996), the therapeutic outcome in
patients receiving reinduction has not been reported. As there is
virtually no information on the optimal duration of chemotherapy
in advanced colorectal cancer in the medical literature, the present
study was undertaken. Our primary goal was to define the potential
therapeutic value of repeating the same treatment after relapse in
patients with metastatic colorectal cancer who had achieved tumour
control (CR, PR or SD) after six monthly courses of first-line
chemotherapy with a 5-day regimen of5-FU/leucovorin or 5-FU/l-
leucovorin.
The present study shows both the limitations and the value of
such a treatment strategy. It also serves to underline certain logistic
difficulties inherent in such a study or any attempt to investigate
reinduction therapy (Coates et al, 1987). Only 49 of 112 patients
who were treated with 5-FU/LV or 5-FU/LLV first-line therapy
were considered eligible for analysis of the reinduction phase of
the study. The decrease in the number of patients entered/eligible
for reinduction was mainly due to the limited effectiveness offirst-
line chemotherapy, including primary treatment failures as well as
the lack of lasting beneficial effects of induction therapy. Because
of the close observation of the study population for recurrent
disease as required by the study protocol, only a minority of our
patients did not meet eligibility factors for reinduction, such as
adequate performance status or hepatic function (which might
have been different in a general patient population in clinical prac-
tice), and only four patients were unwilling to receive further
chemotherapy.
Retreatment of stable responding patients with advanced
colorectal cancer (after a median of 5.4 months without
chemotherapy) with an identical protocol as used for first-line
chemotherapy has resulted in an objective remission rate of 18%
(95% CI 8.8-32%), and no change, i.e. abrogation of further
disease progression in an additional 51Y% of the patients. The
observed overall tumour control rate of69% (95% CI 54.6-81.7%),
median time to second disease progression of 6.4 months and
median survival from the time ofinitiating retreatment of almost 9
months make reinduction an acceptable treatment option for most
first-line chemoresponsive patients. (The overall survival duration
of 20.1 months from the beginning of induction therapy can only
be interpreted in the context of the selected, prognostically
favourable population of patients studied.) The subset of patients
who are most likely to benefit from reinduction seems to be those
with prior CR or PR. These patients had a median survival time of
23.8 months and a response rate of 32% (95% CI, 15-53.5%) on
reinduction. In patients exhibiting SD after induction therapy,
tumour control by reinstitution of initial therapy was obtained in
54%, and this retreatment strategy may also represent an accept-
able therapeutic approach in such patients.
Another advantage of 5-FU/racemic- or LLV reinduction
therapy in advanced colorectal cancer seems to be related to the
low incidence and severity ofadverse reactions noted in this study.
This is despite the fact that patients had a worse performance
status in comparison with the time offirst-line palliative treatment
and may thus have had a somewhat reduced tolerance of
chemotherapy-related side-effects. This observation is most prob-
ably related to the use of a lower starting dose in patients who had
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experienced severe adverse reactions during first-line therapy as
well as the rather stringent hepatic functional parameter inclu-
sion/exclusion criteria for reinduction.
In summary, our data suggest that in patients with advanced
colorectal cancer an interrupted treatment strategy, i.e. reintroduc-
tion of the same treatment regimen in case of relapse .3 months
after discontinuation of 6 months of successful treatment with 5-
FU/LV or 5-FU/LLV is an acceptable therapeutic concept. This
seems particularly true in view of the limited number of other
treatment options that are known to provide clinical benefit after
relapse (and which still can be effected after failure ofreinduction
therapy). Whether intermittent chemotherapy offers any true
advantage over continuous chemotherapy administered until
progression with respect to longevity, morbidity, costs and quality
of life in patients with advanced colorectal cancer can only be
determined in a randomized controlled study. Median survival
times reported in clinical trials using intermittent or continuous 5-
FU/LV seem to be almost identical (Kohne-W6mpert et al, 1992),
a finding that has already been confirmed in randomized trials of
continuous vs discontinuous chemotherapy in advanced breast
cancer (Coates et al, 1987; Muss et al, 1991). According to a
shorter duration of cytotoxic drug administration/treatment-free
interval between induction and reinduction, discontinuous
chemotherapy is likely to offer an advantage in terms of cumula-
tive toxicity, frequency and inconvenience ofhospital visits, costs
of treatment and quality of life. Concerning the latter aspect,
however, a negative (placebo) effect because of patient anxiety
during periods without chemotherapy cannot be entirely excluded
(Coates et al, 1987). A number of other questions remain unan-
swered. These include: (1) whether a treatment duration shorter
than 6 months, e.g. until achievement of best response without
consolidation therapy would be justified/therapeutically equiva-
lent (in view ofa median ofabout 3 months until response in most
trials of 5-FU/LV-based chemotherapy in advanced colorectal
cancer); (2) whether the use of another 5-FU-based salvage
regimen, such as high-dose and/or prolonged 5-FU administration
with or without LV would offer more therapeutic benefit than
reintroduction of the same regimen [in light of the evidence that
infusion and bolus 5-FU therapy seem to have different mecha-
nisms of activity and resistance (Aschele et al, 1992; Wang et al,
1993; Sobrero et al, 1997)]; or (3) whether such attempts should be
reserved for third-line therapy in selected patients. According to
the heterogeneity of the clinical course of advanced colorectal
cancer, an individualized therapeutic strategy will probably remain
the treatment of choice, at least until more definitively effective
treatment options become available.
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